Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent BioSolutions Stock Performance
Shares of Emergent BioSolutions stock opened at $30.50 on Tuesday. Emergent BioSolutions has a one year low of $26.85 and a one year high of $65.09. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 18.05 and a beta of 0.98. The business has a 50-day simple moving average of $31.35 and a 200 day simple moving average of $36.34. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.92 and a quick ratio of 2.38.
Emergent BioSolutions (NYSE:EBS - Get Rating) last issued its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($1.24). Emergent BioSolutions had a net margin of 6.02% and a return on equity of 12.22%. The firm had revenue of $242.70 million during the quarter, compared to the consensus estimate of $268.77 million. During the same period in the previous year, the firm earned $0.33 earnings per share. The business's quarterly revenue was down 38.9% on a year-over-year basis. On average, research analysts anticipate that Emergent BioSolutions will post -0.7 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on EBS. Wells Fargo & Company lowered their target price on Emergent BioSolutions from $46.00 to $38.00 in a research report on Wednesday, May 4th. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Saturday, May 7th. Cowen lowered their price objective on Emergent BioSolutions from $40.00 to $30.00 in a research report on Friday, April 29th. Cowen lowered their price objective on Emergent BioSolutions from $40.00 to $30.00 in a research report on Friday, April 29th. Finally, Chardan Capital lowered their price objective on Emergent BioSolutions from $75.00 to $65.00 in a research report on Friday, April 29th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, Emergent BioSolutions currently has an average rating of "Hold" and a consensus price target of $49.17.
Insider Activity at Emergent BioSolutions
In related news, Director Kathryn C. Zoon sold 1,996 shares of the business's stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $35.53, for a total value of $70,917.88. Following the completion of the sale, the director now directly owns 12,381 shares of the company's stock, valued at approximately $439,896.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Emergent BioSolutions news, Director Kathryn C. Zoon sold 1,996 shares of Emergent BioSolutions stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $35.53, for a total transaction of $70,917.88. Following the completion of the transaction, the director now owns 12,381 shares in the company, valued at approximately $439,896.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathryn C. Zoon sold 1,173 shares of Emergent BioSolutions stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $31.52, for a total value of $36,972.96. Following the transaction, the director now owns 19,654 shares of the company's stock, valued at approximately $619,494.08. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.
